Table 1.
Study | Year | ISS | Stage | N patients | Treatment | Significant factors in multivariate analysis |
---|---|---|---|---|---|---|
Vansteenkiste et al. [1997] | 1997 | 4th? | IIIAN2 | 140 | Surgery | T, PS, n N stations, histology, cN2 |
Suzuki et al. [1999a] | 1999 | 5th | pN2 | 222 | Surgery | cN, T size, n N2 stations, R0 |
Andre et al. [2000] | 2000 | 5th | III | 702 | Surgery | pT, N2, induction CT |
Choi et al. [2002] | 2002 | 4th | pN2 | 101 | Surgery + other | RO, CT use |
Kameyama et al. [2002] | 2002 | 5th | III | 152 | Surgery | Age, R0, pN |
Osaki et al. [2003] | 2003 | 5th | T4N0-2 | 76 | Surgery | pN, R0 |
Lorent et al. [2004] | 2004 | ? | IIIApN2 | 131 | CT → surgery (or RT) | pT, mediastinal downstaging |
Niizeki et al. [2004] | 2004 | 5th | cN2-pN0 | 45 | Surgery | Visceral pleural invasion, CEA level |
Tanaka et al. [2004] | 2004 | 5th | pIIIAN2 | 99 | Surgery → CT or RT | cN2, n N2 stations, MCV (CD105), PI |
Barlesi et al. [2005] | 2005 | 5th | IIIAN2/IIIB | 95/60 | CT → surgery | IIIA: mediastinal downstaging, post-operative complication |
IIIB: vascular invasion | ||||||
Betticher et al. [2006] | 2006 | 5th | IIIApN2 | 75 | CT → surgery | R0, pathological response, mediastinal downstaging |
Tomita et al. [2006] | 2006 | ? | pN2 | 78 | Surgery | None |
Garrido et al. [2007] | 2007 | ? | IIIAN2/IIIB | 136 | CT → surgery | R0, response to induction CT, age |
Kim et al. [2007] | 2007 | ? | IIIAN2 | 66 | CRT → surgery | ypN |
Riquet et al. [2007] | 2007 | 5th | pN2 | 586 | Surgery | Age, pT, one N2 station, adjuvant treatment |
Van Meerbeeck et al. [2007] | 2007 | 5th | IIIAN2 | 332 | CT → surgery or RT | Histology |
Kim et al. [2008] | 2008 | 5th | IIIAN2/dry IIIB | 42 | CT → surgery | Downstaging |
Lee et al. [2008] | 2008 | 5th | IIIAN2 | 262 | Surgery +/− CRT | Age, adjuvant CT, n N2 stations |
Caglar et al. [2009] | 2009 | ? | III | 144 | CRT +/− surgery | Stage, surgery |
Albain et al. [2009] | 2009 | ? | IIIAN2 | 396 | CRT +/− surgery | Weight loss, gender, nN2 stations |
ISS, International Staging System; PS, performance status; R0, complete resection; CT, chemotherapy; CRT, radiochemotherapy; CEA, carcinoembryonic antigen; MCV, microvessel density; PI, proliferative index.